These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 11784625)

  • 21. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
    Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
    Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease.
    Lu TM; Ding YA; Charng MJ; Lin SJ
    Clin Cardiol; 2003 Oct; 26(10):458-64. PubMed ID: 14579916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.
    Kielstein JT; Böger RH; Bode-Böger SM; Frölich JC; Haller H; Ritz E; Fliser D
    J Am Soc Nephrol; 2002 Jan; 13(1):170-176. PubMed ID: 11752034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.
    Cavusoglu E; Ruwende C; Chopra V; Yanamadala S; Eng C; Pinsky DJ; Marmur JD
    Coron Artery Dis; 2009 Mar; 20(2):112-7. PubMed ID: 19240644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease.
    Alsagaff MY; Thaha M; Aminuddin M; Yogiarto RM; Yogiantoro M; Tomino Y
    J Int Med Res; 2012; 40(1):340-9. PubMed ID: 22429374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
    Fliser D; Kronenberg F; Kielstein JT; Morath C; Bode-Böger SM; Haller H; Ritz E
    J Am Soc Nephrol; 2005 Aug; 16(8):2456-61. PubMed ID: 15930091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.
    Zoccali C; Mallamaci F; Maas R; Benedetto FA; Tripepi G; Malatino LS; Cataliotti A; Bellanuova I; Böger R;
    Kidney Int; 2002 Jul; 62(1):339-45. PubMed ID: 12081596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.
    Meinitzer A; Kielstein JT; Pilz S; Drechsler C; Ritz E; Boehm BO; Winkelmann BR; März W
    Clin Chem; 2011 Jan; 57(1):112-21. PubMed ID: 21036946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.
    Zoccali C
    Blood Purif; 2002; 20(5):469-72. PubMed ID: 12207095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study.
    Chang JW; Lee EK; Kim TH; Min WK; Chun S; Lee KU; Kim SB; Park JS
    Am J Nephrol; 2007; 27(1):70-4. PubMed ID: 17259696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symmetrical dimethylarginine predicts mortality in the general population: observations from the Dallas heart study.
    Gore MO; Lüneburg N; Schwedhelm E; Ayers CR; Anderssohn M; Khera A; Atzler D; de Lemos JA; Grant PJ; McGuire DK; Böger RH
    Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2682-8. PubMed ID: 24008162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention.
    Lu TM; Ding YA; Lin SJ; Lee WS; Tai HC
    Eur Heart J; 2003 Nov; 24(21):1912-9. PubMed ID: 14585249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
    Lajer M; Tarnow L; Jorsal A; Teerlink T; Parving HH; Rossing P
    Diabetes Care; 2008 Apr; 31(4):747-52. PubMed ID: 18162497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dimethylarginine levels and nutritional status in hemodialysis patients.
    Cupisti A; Saba A; D'Alessandro C; Meola M; Panicucci E; Panichi V; Raffaelli A; Barsotti G
    J Nephrol; 2009; 22(5):623-9. PubMed ID: 19809995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease.
    van Guldener C; Nanayakkara PW; Stehouwer CD
    Clin Chem Lab Med; 2007; 45(12):1683-7. PubMed ID: 17937610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease.
    Zoccali C; Benedetto FA; Maas R; Mallamaci F; Tripepi G; Salvatore Malatino L; Böger R
    J Am Soc Nephrol; 2002 Feb; 13(2):490-496. PubMed ID: 11805179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients.
    Ebinç FA; Erten Y; Ebinç H; Paşaoğlu H; Demirtaş C; Taçoy G; Mutluay R; Koç E; Derici U; Reis KA; Bali M; Arinsoy T; Sindel S
    Ren Fail; 2008; 30(4):401-6. PubMed ID: 18569913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients.
    Avci E; Coskun S; Cakir E; Kurt Y; Ozgur Akgul E; Bilgi C
    Ren Fail; 2008; 30(8):784-90. PubMed ID: 18791952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding.
    Kielstein JT; Böger RH; Bode-Böger SM; Martens-Lobenhoffer J; Lonnemann G; Frölich JC; Haller H; Fliser D
    Clin Nephrol; 2004 Oct; 62(4):295-300. PubMed ID: 15524060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asymmetric dimethylarginine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients.
    Coen G; Mantella D; Sardella D; Beraldi MP; Ferrari I; Pierantozzi A; Lippi B; Di Giulio S
    J Nephrol; 2009; 22(5):616-22. PubMed ID: 19809994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.